echemi logo
  • Product
  • Supplier
  • Inquiry
    Home > Medical News > Latest Medical News > Zhimeng Pharmaceutical's TLR8 agonist obtains FDA clinical trial approval

    Zhimeng Pharmaceutical's TLR8 agonist obtains FDA clinical trial approval

    • Last Update: 2022-01-11
    • Source: Internet
    • Author: User
    Search more information of high quality chemicals, good prices and reliable suppliers, visit

    Source: Guanlan Pharmaceutical

    Recently, Zhimeng Pharmaceutical announced that the US FDA has approved the clinical trial application of its small molecule oral TLR8 agonist CB06-036
    CB06-036 is a drug candidate for the treatment of chronic hepatitis B, independently developed by Zhimeng Pharmaceutical


    As a TLR8 agonist, CB06-036 has shown good selectivity, activity and safety in preclinical studies.
    It can induce cytokines in human peripheral blood mononuclear cells.
    These cytokines can pass through a variety of immune mediators.
    , Activate the anti-virus function

    At the same time, it has also been found to have good liver targeting characteristics

    Based on this license, Zhimeng Medicine is about to start a phase 1 clinical trial in the United States, which will use healthy volunteers as subjects to evaluate the safety and tolerability of CB06-036 after oral ascending doses, and to determine the effectiveness of the drug in the body.
    Research on kinetics and pharmacodynamics


    This article is an English version of an article which is originally in the Chinese language on and is provided for information purposes only. This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed description of the concern or complaint, to A staff member will contact you within 5 working days. Once verified, infringing content will be removed immediately.

    Related Articles

    Contact Us

    The source of this page with content of products and services is from Internet, which doesn't represent ECHEMI's opinion. If you have any queries, please write to It will be replied within 5 days.

    Moreover, if you find any instances of plagiarism from the page, please send email to with relevant evidence.